- Home
- EDTK vs NRSN Comparison
EDTK vs NRSN Comparison
Compare EDTK & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- NRSN
- Stock Information
- Founded
- EDTK 2013
- NRSN 2017
- Country
- EDTK China
- NRSN Israel
- Employees
- EDTK N/A
- NRSN N/A
- Industry
- EDTK Other Consumer Services
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- NRSN Health Care
- Exchange
- EDTK Nasdaq
- NRSN Nasdaq
- Market Cap
- EDTK 16.6M
- NRSN 17.8M
- IPO Year
- EDTK 2020
- NRSN 2021
- Fundamental
- Price
- EDTK $1.10
- NRSN $1.09
- Analyst Decision
- EDTK
- NRSN Hold
- Analyst Count
- EDTK 0
- NRSN 1
- Target Price
- EDTK N/A
- NRSN N/A
- AVG Volume (30 Days)
- EDTK 10.4K
- NRSN 374.5K
- Earning Date
- EDTK 01-24-2025
- NRSN 12-18-2024
- Dividend Yield
- EDTK N/A
- NRSN N/A
- EPS Growth
- EDTK N/A
- NRSN N/A
- EPS
- EDTK N/A
- NRSN N/A
- Revenue
- EDTK $624,365.00
- NRSN N/A
- Revenue This Year
- EDTK N/A
- NRSN N/A
- Revenue Next Year
- EDTK N/A
- NRSN N/A
- P/E Ratio
- EDTK N/A
- NRSN N/A
- Revenue Growth
- EDTK N/A
- NRSN N/A
- 52 Week Low
- EDTK $0.77
- NRSN $0.51
- 52 Week High
- EDTK $1.27
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- EDTK 53.34
- NRSN 47.35
- Support Level
- EDTK $1.05
- NRSN $1.01
- Resistance Level
- EDTK $1.20
- NRSN $1.13
- Average True Range (ATR)
- EDTK 0.07
- NRSN 0.09
- MACD
- EDTK 0.01
- NRSN -0.01
- Stochastic Oscillator
- EDTK 65.16
- NRSN 27.27
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.